LaFleur & Godfrey LLC raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 6.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 138,853 shares of the company's stock after purchasing an additional 8,964 shares during the quarter. Johnson & Johnson comprises approximately 3.1% of LaFleur & Godfrey LLC's investment portfolio, making the stock its 6th biggest holding. LaFleur & Godfrey LLC's holdings in Johnson & Johnson were worth $23,027,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $29,000. Conquis Financial LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $33,000. Bernard Wealth Management Corp. acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $36,000. Finally, Highline Wealth Partners LLC grew its position in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Stock Performance
JNJ traded down $0.03 during midday trading on Thursday, reaching $152.25. The company's stock had a trading volume of 7,147,500 shares, compared to its average volume of 9,171,523. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The company has a fifty day simple moving average of $153.95 and a 200 day simple moving average of $153.67. The stock has a market cap of $366.33 billion, a P/E ratio of 16.94, a PEG ratio of 2.31 and a beta of 0.42. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.42%. The ex-dividend date of this dividend was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on JNJ shares. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Barclays cut their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $170.88.
Read Our Latest Research Report on Johnson & Johnson
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
